In its first major M&A move under new CEO Luke Miels, GSK has reached a definitive agreement to acquire California-based Rapt Therapeutics for $2.2 billion. The deal positions the British pharmaceutical giant as a formidable player in the multi-billion dollar food allergy market.
Spotlight on ozureprubart technology The acquisition grants GSK global rights (excluding mainland China, Taiwan, Hong Kong, and Macau) to ozureprubart, an investigational long-acting anti-IgE monoclonal antibody. Currently in Phase 2b clinical trials, the drug is designed to provide prophylactic protection against severe allergic reactions.
Key advantages of ozureprubart over existing therapies:
-
Extended Dosing Interval: The drug offers the potential for injections every 12 weeks, a significant improvement over the current standard of every 2 to 4 weeks.
-
Increased Inclusivity: Ozureprubart may provide a new option for approximately 25% of patients who are currently ineligible for existing anti-IgE treatments due to high body weight or elevated IgE levels.
-
Blockbuster Potential: With over 17 million food allergy sufferers in the U.S. alone, analysts view this as a “multi-blockbuster” opportunity in a market estimated to be worth over $10 billion.
GSK’s Strategic Pivot This acquisition aligns with GSK’s broader strategy to strengthen its immunology and respiratory pipeline. By absorbing Rapt’s technology, GSK aims to offset looming revenue declines from patent expirations in its legacy portfolio. The deal follows other recent organizational shifts, including the restructuring of the ViiV Healthcare partnership.
The transaction is expected to close in the first quarter of 2026, with pivotal Phase 2b data anticipated in 2027.